Malignant cells, directors of the malignant process: Role of transforming growth factor-beta

Cancer and Metastasis Reviews

Volumn 20, Issue 1-2, 2001, Pages 133-143

  Teicher, Beverly A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Combination therapy; Malignancy; Transforming growth factor beta; Xenograft tumors

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CARCINOGENICITY; CELL SURVIVAL; DIGESTIVE SYSTEM CANCER; EXTRACELLULAR MATRIX; GENE MUTATION; GENITAL TRACT CANCER; GLIOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CELL DIFFERENTIATION; CELL DIVISION; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 0035689762     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013177011767     Document Type: Article

References (180)

1. Cancer models: Manipulating the transforming growth factor-β pathway in mice
2. TGF-beta knockout and dominant-negative receptor transgenic mice
3. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis
4. The role of transcription factors involved in TGFbeta superfamily signaling during development
5. Role of transforming growth factor-β in tissue injury and repair
6. Transforming growth factor-β: A general review
7. Growth factors in mechanisms of malignancy: Roles for TGF-β and FGF
8. Specificity, diversity and regulation in TGF-β superfamily signaling
9. TGF-β signaling pathways and human diseases
10. The role for transforming growth factor-β (TGF-β) in human cancer
11. TGF-β and cancer
12. Specificity, diversity and regulation in TGF-β superfamily signaling
13. The transforming growth factor-β signaling pathway in tumorigenesis
14. Signaling of transforming growth factor-β family members through Smad proteins
15. TGF-β autoccrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells
16. Transcriptional control by the TGF-β/Smad signaling system
17. Identification of transforming growth factor-β1-binding protein overexpression in carmustine-resistant glioma cells by mRNA differential display
18. Disruption of TGF-β growth inhibition by oncogenic ras is linked to p27kip1 mislocalization
19. TβR-1(6A) is a candidate tumor susceptibility allele
20. Modulation of sensitivity to transforming growth factor-β1 (TGF-β1) and the level of type II TGF-β receptor in LNCaP cells by dihydrotestosterone
21. Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens
22. Decorin inhibits cell attachement to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1
23. Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer
24. Transforming growth factor-β complexes with thrombospondin
25. Angiogenesis and cancer metastasis
26. Imaging of tumor neovasculature by targeting the TGF-β binding receptor endoglin
27. Role of transforming growth factor-β signaling in cancer
28. Drug resistance and gene amplification potential regulated by transforming growth factor β1 gene expression
29. Transforming growth factor β1 secreted from scirrhoous gastric cancer cells is associated with excess collagen deposition in the tissue
30. Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin
31. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma
32. Transforming growth factor-β in in vivo resistance
33. Transforming growth factor-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
34. Protection of bone-marrow granulocyte-macrophage colony-forming units in mice beating in vivo alkylating agent resistant EMT-6 tumors
35. Molecular characterization of the in vivo alkylating agent resistant murine EMT-6 mammary carcinoma tumors
36. Acquired multicellular-mediated resistance to alkylating agents in cancer
37. Transforming growth factor-β in in vivo resistance
38. Transforming growth factor-β and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo
39. Transforming growth factor-β overexpression produces drug resistance in vivo: Reversal by decorin
40. Transforming growth factor-β and prostate cancer
41. Down-regulation of protein and mRNA expression for transforming growth factor-β (TGF-β) type I and type II receptors in human prostate cancer
42. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues
43. Reduced levels of transforming growth factor β receptor type II in human prostate cancer: An immunohistochemical study
44. Identifying breast cancer patients at high risk for bone metastases
45. Invasion and metasasis of a mammary tumor involves TGF-β signaling
46. Mechanism of transforming growth factor-β1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells
47. Human breast-cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants
48. TGF-b signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
49. Transforming growth factor-β1 gene polymorphism and bone mineral density
50. Human breast cancer cells induce angiogenesis, recruitment and activation of osteoclasts in osteolytic metastasis
51. Association between the T29 -> C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women
52. Induction of transforming growth factor beta in hormonally treated human prostate cancer
53. Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells
54. TGF-β: A critical modulator of immune cell function
55. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity
56. Augmentation of host immune responses to cancer: Overcoming the barrier of tumor antigen-specific T-cell tolerance
57. Transforming growth factor-beta-induced inhibition of T cell function. Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosupression in the tumor-bearing state
58. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance
59. Expression of an antisense transforming growth factor-b1 transgene reduces tumorigenicity of EMT6 mammary tumor cells
60. Reversal of tumor-induced immunosupression: A new approach to cancer therapy
61. Down-regulation of TGF-b1 production restores immunogenicity in prostate cancer cells
62. Transforming growth factor-β1 inhibition of macrophage activation is mediated via Smad3
63. Transforming growth factor-β negatively modulates T-cell responses in sepsis
64. A role for TGFβ1 in Langerhans cell biology: Further characterization of the epidermal langerhans cell defect in TGFβ null mice
65. Extracellular matrix is reduced by inhibition of transforming growth factor b1 in pancreatitis in the rat
66. In vitro restoration of T-cell responses in tuberculosis and augmentation of monocyte effector function against mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta
67. Trypanosome invasion of mammalian cells requires activation of the TGF-beta signaling pathway
68. Transforming growth factor-beta in leishmanial infection: A parasite escape mechanism
69. How tumors escape immune destruction and what we can do about it
70. Improvement of macrophage dysfunction by administration of anti-transforming growth factor-β antibody in EL4-bearing hosts
71. Regulation of immune responses by TGF-beta
72. TGFβ1 and TGFβ2 are potential growth regulators for medulloblastomas, primitive neuroectodermal tumors, and ependymomas: Evidence in support of an autocrine hypothesis
73. Decorin gene transfer-mediated supression of TGF-beta synthesis abrogates experimental glioma growth in vivo
74. Expression of transforming growth factor beta mRNA isoforms in human breast cancer
75. Transforming growth factor-β1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer
76. Comparison between oestrogen receptor and transforming growth factor β in breast cancer
77. Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma
78. The effect of endocrine therapy on the levels of oestrogen and progesterone receptor and transforming growth factorβ1 in metastatic human breast cancer: An immunocytochemical study
79. Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy
80. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell-derived members of the transforming growth factor β in breast cancer
81. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
82. Early gene responses associated with transforming growth factor-β1 growth inhibition and autoinduction in MCF-7 (transforming growth factor-β1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells
83. Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7
84. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells
85. Regulation of transforming growth factor β1 by radiation in cells of two human breast cancer cell lines
86. Evidence for a positive role of transforming growth factor-β in human breast cancer cell tumorgenesis
87. Transforming growth factor β1 can induce estrogen-independent tumorgenicity of human breast cancer cells in athymic mice
88. Correlation of TGF-β expression with medroxiprogesterone acetate responsiveness in mouse mammary adenocarcinomas
89. Multiple forms of TGF-β1 in breast tissues: Biologically breast adenocarcinoma cells
90. Expression of transforming growth factor β type III receptor supresses tumorigenicity of human breast cancer MDA-MB-231 cells
91. A soluble transforming growth factor β type III receptor supresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells
92. In vitro growth inhibition of ovarian cancer cells by decorin: Synergism between decorin and carboplatin
93. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma
94. Transforming growth factor-β (TGF-β) mRNA expression and growth control in human lung squamous carcinoma cell lines
95. Thrombospondin (TSP) and transforming growth factor beta1 (TGF-β) promote human A549 lung carcinoma cell plasminogen activator inhibitor type I (PAI-1) production and stimulate tumor cell attachment in vitro
96. Expression and autoregulation of transforming growth factor β receptor mRNA in small-cell lung cancer cell lines
97. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis
98. Changes in plasma TGFβ levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis
99. Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma
100. Positive correlation of plasma transforming growth factor-β1 levels with tumor vascularity in hepatocellular carcinoma
101. Elevated urinary transforming growth factor-β1 level as a tumor marker and predictor of poor survival in cirrhotic hepatocellular carcinoma
102. Transforming growth factor-β1 and a in chronic liver disease
103. Transforming growth factor β1 and a in chronic liver disease: Effects of interferon-α therapy
104. Transforming growth factor-β1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic and neoplastic human livers
105. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma
106. Autocrine stimulatory mechanism by transforming growth factor β in human hepatocellular carinoma
107. Elevated levels of transforming growth factor β messenger RNA and its polypeptide in human hepatocellular carcinoma
108. Constitutive expression of mature transforming growth factor β1 in the liver accelerates hepatocarcinogenesis in transgenic mice
109. TGF-β-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes
110. Differentially expressed genes in TGF-β1 sensitive and resistant human hepatoma cells
111. Expression of transforming growth factor-β1 during chemical hepatocarcinogenesis in the rat
112. Liver promotion: Effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-β1 expression
113. Transforming growth factor-β (TGF-β) isoforms in rat liver regeneration: Messenger RNA expression and activation of latent TGF-β
114. Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-β1 during liver regeneration
115. Cellular distribution of transforming growth factor-β1 and procollagen types I, III and IV transcripts in carbon tetrachloride-induced rat liver fibrosis
116. In vitro and in vivo association of transforming growth factor-β1 with hepatic fibrosis
117. Development of resistance to the growth inhibitory effects of transforming growth factor β1 during the spontaneous transformation of rat liver epithelial cells
118. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor β type II receptor: A potential new therapy for hepatic fibrosis
119. Transforming growth factor-β1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture
120. Differentially expressed genes in TGF-β1 sensitive and resistant human hepatoma cells
121. Suppression of antioxidative enzyme expression by transforming growth factor-β1 in rat hepatocytes
122. Oxygen regulation of TGF-β1 mRNA in human hepatoma (HEP G2) cells
123. Hepatic expression of mature transforming growth factor β1 in transgenic mice results in multiple tissue lesions
124. Effects of transforming growth factor β1 on the adenylyl cyclase-cAMP pathway in prostate cancer
125. Transforming growth factor-β1 over-production in prostate cancer: Effects on growth in vivo and in vitro
126. Expression of transforming growth factor-β1 in prostate cancer
127. Transforming growth factor-β in benign and malignant prostate
128. Regulation of prostatic stromal cell growth and function by transforming growth factor beta (TGFβ)
129. Loss of responsiveness to transforming growth factor β induces malignant transformation of non-tumorigenic rat prostate epithelial cells
130. Differential expression of transforming growth factor-β1 and β3 as well as C-FOS mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer
131. TGFβ in prostate cancer: A growth inhibitor that can enhance tumorigenicity
132. Induction of transforming growth factor beta in hormonally treated human prostate cancer
133. Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death
134. Effect of transforming growth factor-β1 on proliferation and death of rat prostatic cells
135. Regulation of apoptosis induced by transforming growth factor-β1 in non-tumorigenic and tumorigenic rat prostatic epithelial cell lines
136. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers
137. Peptide growth factors and their receptors
138. TGF-β stimulation and inhibition of cell proliferation: New mechanistic insights
139. Growth factor balance and tumor progression
140. A benign cultured colon adenoma bears three genetically altered colon cancer oncogenes, but progresses to tumorigenicity and transforming growth factor-β independence without inactivating the p53 tumor supressor gene
141. Development of resistance mechanisms to the growth inhibitory effects of transforming growth factor-β during tumor progression
142. Microsatellite instability in inherited and sporadic neoplasms
143. Hereditary nonpolyposis colorectal cancer: The syndrome, the genes and historical perspectives
144. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
145. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer
146. Mutational analysis of the transforming growth factor β receptor type II gene in hereditary nonpolyosis colorectal cancer and early-onset colorectal cancer patients
147. Distribution of transforming growth factor-β and its receptors in gastric carcinoma tissue
148. Transforming growth factor β1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue
149. Anti-tumor effects of recombinant human macrophage colony-stimulating factor, alone or in combination with local irradiation, in mice inoculated with Lewis lung carcinoma cells
150. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer
151. A transforming growth factor β receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
152. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells
153. Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression
154. Mutations of the transforming growth factor β type II receptor gene and microsatellite instability in gastric cancer
155. Distribution of transforming growth factor-β and its receptors in gastric carcinoma tissue
156. Transforming growth factor β1 secreted from scirrhous gastric cancer cells is associated with excess collagen deposition in the tissue
157. Defective transforming growth factor β signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2
158. Involvement of transforming growth factor β1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells
159. 1 in the fibroblastic reaction associated with rat colorectal tumor development
160. Expression of transforming growth factor β1, β2, β3 in neuroendocrine tumors of the digestive system
161. TGF-b1 up-regulates cyclin D1 expression of COLO-357 cells, whereas supression of cyclin D1 levels is associated with down-regulation of the type 1 TGF-β receptor
162. Acquisition of TGF-β1 resistance: An important factor in human renal cell carcinoma
163. Increased expression of transforming growth factor β isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium: Evidence for paracrine and autocrine action
164. Transforming growth factor β mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium
165. Decreased growth inhibitory response of primary cultures of endometrial carcinoma cells to TGF-beta1 is accompanied by altered response to gonadal steroids
166. Transforming growth factor-beta-related mechanisms of loss of growth control in endometrial carcinoma
167. Immunocytochemical localization of transforming growth factors (TGFs) TGF-β and TGF-β in human ovarian tissues
168. Transforming growth factor-β1 regulation of metalloproteinase production in cultured human cervical epithelial cells
169. Control of human glioma cell growth, migration and invasion pp. in vitro by transforming growth factor β1
170. Retroviral-mediated transduction of p53 gene increases TGF-β expression in a human glioblastoma cell line
171. Enhanced expression of transforming growth factor-β and its type-I and type-II receptors in human glioblastoma
172. Production of TGFβ and HGF
173. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro
174. Inhibition of skin development by overexpression of transforming growth factor β1 in the epidermis of transgenic mice
175. Transforming growth factor β production and responsiveness in normal human melanocytes and melanoma cells
176. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice
177. Expression of transforming growth factorβ1 in mouse skin during the acute phase of radiation damage
178. Transforming growth factor β1 (TGFβ1) expression in proliferating thyroid disease
179. A systems approach to cancer therapy (antiangiogenics + standard cytotoxics' mechanism(s) of interaction)